EA201991692A1 - Иммуносконструированные плюрипотентные клетки - Google Patents

Иммуносконструированные плюрипотентные клетки

Info

Publication number
EA201991692A1
EA201991692A1 EA201991692A EA201991692A EA201991692A1 EA 201991692 A1 EA201991692 A1 EA 201991692A1 EA 201991692 A EA201991692 A EA 201991692A EA 201991692 A EA201991692 A EA 201991692A EA 201991692 A1 EA201991692 A1 EA 201991692A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pluripotent cells
cells
immuno
designed
relates
Prior art date
Application number
EA201991692A
Other languages
English (en)
Russian (ru)
Inventor
Тоня Шрепфер
Тобиас Дойзе
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA201991692A1 publication Critical patent/EA201991692A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/005—Vectors comprising a special translation-regulating system cell cycle specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01021—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201991692A 2017-01-13 2018-01-14 Иммуносконструированные плюрипотентные клетки EA201991692A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762445969P 2017-01-13 2017-01-13
PCT/US2018/013688 WO2018132783A1 (en) 2017-01-13 2018-01-14 Immunoengineered pluripotent cells

Publications (1)

Publication Number Publication Date
EA201991692A1 true EA201991692A1 (ru) 2019-12-30

Family

ID=61148505

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991692A EA201991692A1 (ru) 2017-01-13 2018-01-14 Иммуносконструированные плюрипотентные клетки

Country Status (12)

Country Link
US (2) US20190376045A1 (https=)
EP (1) EP3568464A1 (https=)
JP (3) JP2020505025A (https=)
KR (2) KR20190103373A (https=)
CN (1) CN110177869A (https=)
AU (2) AU2018207649B2 (https=)
BR (1) BR112019014257A2 (https=)
CA (1) CA3049766A1 (https=)
EA (1) EA201991692A1 (https=)
IL (1) IL267616A (https=)
MX (1) MX2019008413A (https=)
WO (1) WO2018132783A1 (https=)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059378A (zh) 2014-12-10 2023-05-05 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
CN107921148A (zh) 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
JP2020505025A (ja) * 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
CA3094322A1 (en) * 2017-03-20 2018-09-27 Washington University Cells and methods of uses and making the same
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
IL270835B2 (en) 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2020018620A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Chimeric antigen receptor t cells derived from immunoengineered pluripotent stem cells
CA3109078A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Cells differentiated from immunoengineered pluripotent cells
US12378572B2 (en) * 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
WO2020067993A1 (en) * 2018-09-26 2020-04-02 National University Of Singapore Engineered human mesenchymal stromal cells with low immunogenicity, methods and kits of generating the same
UY38427A (es) * 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
CN111424016A (zh) * 2019-01-09 2020-07-17 复旦大学 降低细胞免疫原性的诱导型多能干细胞系及建立方法
KR20210128440A (ko) * 2019-02-15 2021-10-26 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 범용 공여자 줄기 세포 및 관련 방법
US12221622B2 (en) * 2019-05-10 2025-02-11 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
CA3144621A1 (en) 2019-06-26 2020-12-30 The Regents Of The University Of California Sirpalpha-silenced natural killer (nk) cells
TW202115245A (zh) * 2019-06-27 2021-04-16 丹麥商諾佛 儂迪克股份有限公司 安全免疫隱形細胞
US20220333082A1 (en) 2019-07-10 2022-10-20 Helmuth Heinrich Kunz Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
US20220267732A1 (en) * 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
PH12022550542A1 (en) 2019-09-05 2023-03-20 Crispr Therapeutics Ag Universal donor cells
CA3150235A1 (en) * 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
WO2021050601A1 (en) * 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
WO2021055985A1 (en) * 2019-09-22 2021-03-25 Cellerant Therapeutics, Inc. Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
CN114787351A (zh) * 2019-10-15 2022-07-22 加利福尼亚大学董事会 通过Fc隔离的移植细胞保护
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
WO2021146471A2 (en) 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
KR20220142433A (ko) 2020-01-17 2022-10-21 사나 바이오테크놀로지, 인크. 유전자 발현 조절용 안전 스위치
KR20220158046A (ko) * 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
US20230374448A1 (en) * 2020-04-06 2023-11-23 Rxcell Inc. Hypoimmunogenic Cells and Methods and Compositions for Their Production
EP4138893A4 (en) * 2020-04-21 2024-06-12 Intima Bioscience, Inc. CELLULAR VACCINE PLATFORM AND METHODS OF USE THEREOF
EP4149525A4 (en) * 2020-05-15 2024-08-28 Rxcell Inc. HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
CN112342196A (zh) * 2020-08-18 2021-02-09 未来智人再生医学研究院(广州)有限公司 一种免疫兼容可逆的通用型多能干细胞及其应用
WO2022076928A1 (en) * 2020-10-09 2022-04-14 Sana Biotechnology, Inc. METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRPα BLOCKADE AGENT
EP4232468A4 (en) * 2020-10-20 2025-03-19 Replay Holdings, Inc. Methods and compositions for cellular therapy
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
CN114457021A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd47抗体的多能干细胞及其衍生物与应用
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
CN114107211B (zh) * 2020-12-04 2025-09-30 未来智人再生医学研究院(广州)有限公司 一种多能干细胞及其衍生物
WO2022125439A2 (en) * 2020-12-07 2022-06-16 The Regents Of The University Of California Innate immune cell silencing by sirp-alpha engager
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
WO2022144855A1 (en) 2020-12-31 2022-07-07 Crispr Therapeutics Ag Universal donor cells
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
JPWO2022191216A1 (https=) * 2021-03-09 2022-09-15
EP4313087A4 (en) * 2021-03-30 2025-03-19 The Regents of the University of California PROTECTION OF TRANSPLANTED CELLS VIA MODIFIED FC RECEPTORS
KR20240007651A (ko) * 2021-04-16 2024-01-16 빔 테라퓨틱스, 인크. 간세포의 유전적 변형
AU2022281328A1 (en) * 2021-05-24 2023-12-07 Sangamo Therapeutics, Inc. Ciita targeting zinc finger nucleases
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023008918A1 (ko) * 2021-07-28 2023-02-02 의료법인 성광의료재단 B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
EP4384598A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
AU2022327174A1 (en) 2021-08-11 2024-02-15 Sana Biotechnology, Inc. Inducible systems for altering gene expression in hypoimmunogenic cells
CN117904109A (zh) * 2021-08-27 2024-04-19 浙江大学 一种超级增强子核心序列调控b2m基因表达的效果及应用
US20250313861A1 (en) 2021-10-22 2025-10-09 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
CN119072319A (zh) 2021-12-23 2024-12-03 萨那生物技术股份有限公司 用于治疗自身免疫性疾病的嵌合抗原受体(car)t细胞及相关方法
KR20240142624A (ko) * 2022-01-10 2024-09-30 사나 바이오테크놀로지, 인크. 만능줄기세포에서 분화된 면역저하 베타세포 및 관련 용도 및 방법
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
EP4479416A1 (en) 2022-02-17 2024-12-25 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
CN114958768B (zh) * 2022-06-02 2023-03-24 健颐生物科技发展(山东)有限公司 Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
CN117343962A (zh) * 2022-06-29 2024-01-05 中国科学院上海营养与健康研究所 免疫兼容型人多能干细胞、其制备方法及应用
US20260002124A1 (en) 2022-07-01 2026-01-01 Novo Nordisk A/S Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
WO2024012420A1 (zh) * 2022-07-11 2024-01-18 士泽生物医药（苏州）有限公司 一种表达faslg的通用型细胞及其制备方法
CN117431217A (zh) * 2022-07-12 2024-01-23 上海驯鹿生物技术有限公司 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
GB202211117D0 (en) * 2022-07-29 2022-09-14 Replay Holdings Llc Compositions and methods for non-immunogenecity
GB202212144D0 (en) * 2022-08-19 2022-10-05 Resolution Therapeutics Ltd Cells for therapy
WO2024097313A1 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Methods for producing t cell therapy products
EP4619015A1 (en) * 2022-11-15 2025-09-24 The Board of Trustees of the Leland Stanford Junior University Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
CN118147077B (zh) * 2022-12-07 2025-09-26 士泽生物医药（苏州）有限公司 一种表达gsn的通用型细胞及其制备方法
CN118207165B (zh) * 2022-12-07 2026-03-20 士泽生物医药（苏州）有限公司 一种表达stc1的通用型细胞及其制备方法
GB202218755D0 (en) * 2022-12-13 2023-01-25 Replay Holdings Llc Compositions and methods for non-immunogenicity
WO2024125592A1 (zh) * 2022-12-16 2024-06-20 士泽生物医药（苏州）有限公司 一种通用型细胞及其制备方法
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024169917A1 (zh) * 2023-02-16 2024-08-22 士泽生物医药（苏州）有限公司 通用型细胞及其制备方法
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
EP4716541A2 (en) 2023-05-22 2026-04-01 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
EP4735585A1 (en) 2023-06-30 2026-05-06 Novo Nordisk A/S Enhancing neuronal differentiation of neural progenitor cells
KR102740042B1 (ko) * 2023-07-12 2024-12-06 ㈜바이오솔빅스 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
CN119351338B (zh) * 2023-09-15 2026-01-23 士泽生物医药（苏州）有限公司 一种表达cd300ld的低免疫原性细胞及其制备方法
WO2025096757A1 (en) 2023-11-01 2025-05-08 Sana Biotechnology, Inc. Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025230947A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Engineered hepatocytes for secreting polypeptides
WO2025230941A1 (en) 2024-04-30 2025-11-06 Satellite Biosciences, Inc. Hypoimmunogenic cell mixtures and methods of use thereof
CN121006322A (zh) * 2024-05-22 2025-11-25 上海苹谱医疗科技有限公司 一种通用型工程化细胞及其制备方法与应用
WO2025259640A1 (en) * 2024-06-14 2025-12-18 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for bioengineering hypoimmunogenic organs, tissues and cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US20040053836A1 (en) * 2002-04-22 2004-03-18 Philipp Mayer-Kuckuk Method for modulating the production of a selected protein in vivo
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010141801A2 (en) * 2009-06-05 2010-12-09 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
FI2838548T3 (fi) * 2012-04-17 2023-10-02 Univ Washington Through Its Center For Commercialization HLA:n luokan II puutteelliset solut, HLA:n luokan II puutteelliset solut, jotka kykenevät ilmentämään HLA:n luokan II proteiineja, ja niiden käytöt
EP3114217A4 (en) * 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Caspase polypeptides having modified activity and uses thereof
KR20200138445A (ko) * 2014-04-24 2020-12-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
JP2018509148A (ja) * 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
CN107921148A (zh) * 2015-05-08 2018-04-17 哈佛学院校长同事会 通用供体干细胞和相关方法
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
JP2020505025A (ja) * 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
US12221622B2 (en) * 2019-05-10 2025-02-11 The Regents Of The University Of California Modified pluripotent cells

Also Published As

Publication number Publication date
JP2025069169A (ja) 2025-04-30
WO2018132783A1 (en) 2018-07-19
MX2019008413A (es) 2019-09-13
EP3568464A1 (en) 2019-11-20
US20230348862A1 (en) 2023-11-02
US20190376045A1 (en) 2019-12-12
KR20240095477A (ko) 2024-06-25
BR112019014257A2 (pt) 2020-04-28
AU2018207649A1 (en) 2019-07-11
IL267616A (en) 2019-08-29
JP2020505025A (ja) 2020-02-20
CA3049766A1 (en) 2018-07-19
CN110177869A (zh) 2019-08-27
AU2024256086A1 (en) 2024-11-28
AU2018207649B2 (en) 2024-08-01
JP2023052079A (ja) 2023-04-11
NZ754898A (en) 2023-11-24
KR20190103373A (ko) 2019-09-04

Similar Documents

Publication Publication Date Title
EA201991692A1 (ru) Иммуносконструированные плюрипотентные клетки
MX2025004255A (es) Celulas diferenciadas de celulas pluripotentes inmunodise?adas
DOP2021000022A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
MX2025001919A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2023014093A (es) Compuestos que interactuan con glicano y metodos de uso.
MX2020001513A (es) Agentes de union a clec9a y su uso.
CY1118105T1 (el) Αγγειογενεση χρησιμοποιωντας πλακουντιακα βλαστικα κυτταρα
GEAP202115055A (en) Anti-cd27 antibodies
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
CY1124143T1 (el) Οστικες μορφογενετικες πρωτεϊνες
SA523440622B1 (ar) أجسام مضادة
TN2018000021A1 (en) ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
CY1126032T1 (el) Συζευγματα αντισωματος-φαρμακου που στοχευουν uparap
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX377300B (es) Terapia con células madre en patologías endometriales.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib